Lack of PPCA Expression only Partially Coincides with Lysosomal Storage in Galactosialidosis Mice: Indirect Evidence for Spatial Requirement of the Catalytic Rather than the Protective Function of PPCA
Abstract
Protective protein/cathepsin A (PPCA) is a pleiotropic lysosomal enzyme that complexes with beta-galactosidase and neuraminidase, and possesses serine carboxypeptidase activity. Its deficiency in man results in the neurodegenerative lysosomal storage disorder galactosialidosis (GS). The mouse model of this disease resembles the human early onset phenotype and results in severe nephropathy and ataxia. To understand better the pathophysiology of the disease, we compared the occurrence of lysosomal PPCA mRNA and protein in normal adult mouse tissues with the incidence of lysosomal storage in PPCA(-/-) mice. PPCA expression was markedly variable among different tissues. Most sites that produced both mRNA and protein at high levels in normal mice showed extensive and overt storage in the knockout mice. However, this correlation was not consistent as some cells that normally expressed high levels of PPCA were unaffected in their storage capability in the PPCA(-/-) mice. In addition, some normally low expressing cells accumulated large amounts of undegraded products in the GS mouse. This apparent discrepancy may reflect a requirement for the catalytic rather than the protective function of PPCA and/or the presence of cell-specific substrates in certain cell types. A detailed map showing the cellular distribution of PPCA in nomal mouse tissues as well as the sites of lysosomal storage in deficient mice is critical for accurate assessment of the effects of therapeutic interventions.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ppca−/− mice have a clinical and pathological presentation that closely recapitulates early onset forms of GS, with no cathepsin A activity, severe secondary Neu1 deficiency, and β-Gal partially reduced only in some cell types.
“These mice have a clinical and pathological presentation that closely recapitulates the early onset forms of GS (Figure 2).”
From Galactosialidosis: historic aspects and overview of investigated and emerging treatment options (2017) · cites this paper as [54]
Cited by
Sorted by citations
Galactosialidosis: historic aspects and overview of investigated and emerging treatment options
Annunziata, I., & d’Azzo, A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1266933 · Cited by 50 · see citing works
Self-citationHermo, L., Korah, N., Gregory, M., Liu, L. Y., Cyr, D. G., D'Azzo, A., & Smith, C. E. (2007) · Journal of Andrology · doi:10.2164/jandrol.107.002980 · Cited by 27 · see citing works
Self-citation
- Authors
- Rottier, R. J., Hahn, C. N., Mann, L. W., Martin, M. D. P., Smeyne, R. J., Suzuki, K., & d'Azzo, A.
- Affiliations
- St. Jude Children's Research Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-10-01
- Volume
- 7
- Issue
- 11
- Pages
- 1787-1794
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2104656101
- Cited by
- 25
- References
- 0
- Citations by year
- 2022: 1 · 2016: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Assisi Foundation of Memphis
- American Lebanese Syrian Associated Charities (CA 21765)
- National Institutes of Health (CA21765))
- National Institute of Diabetes and Digestive and Kidney Diseases (1-RO1-DK32025-01)
- National Institute of Neurological Disorders and Stroke (1-RO1-NS24533)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD003110)
- Topics
- Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Rheumatology › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- PpcA, galactosialidosis, lysosomal storage disease, tissue-specific gene expression, beta-galactosidase, neuraminidase, lysosomal storage, kidney disease, ataxia
- MeSH terms
- Animals, Brain, Carboxypeptidases, Epididymis, Female, Immunohistochemistry, Intestines, Liver, Male, Mice, Inbred Strains, Ovary, Spleen, Testis, Uterus, Lysosomal Storage Diseases, In Situ Hybridization, Mice, Knockout, Cathepsin A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review